<VariationArchive VariationID="522614" VariationName="NM_023067.4(FOXL2):c.462_468del (p.Pro156fs)" VariationType="Deletion" Accession="VCV000522614" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-23" DateCreated="2018-04-29" MostRecentSubmission="2018-04-29">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="513226" VariationID="522614">
      <GeneList>
        <Gene Symbol="FOXL2" FullName="forkhead box L2" GeneID="668" HGNC_ID="HGNC:1092" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>3q22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="138944224" stop="138947137" display_start="138944224" display_stop="138947137" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="138663065" stop="138665981" display_start="138663065" display_stop="138665981" Strand="-" />
          </Location>
          <OMIM>605597</OMIM>
          <Haploinsufficiency last_evaluated="2021-02-09" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FOXL2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-02-09" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FOXL2">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_023067.4(FOXL2):c.462_468del (p.Pro156fs)</Name>
      <CanonicalSPDI>NC_000003.12:138946254:CGGCGGCCGG:CGG</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>3q22.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="138946255" stop="138946261" display_start="138946255" display_stop="138946261" variantLength="7" positionVCF="138946254" referenceAlleleVCF="GCGGCGGC" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="138665097" stop="138665103" display_start="138665097" display_stop="138665103" variantLength="7" positionVCF="138665096" referenceAlleleVCF="GCGGCGGC" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>P156fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.138665100_138665106del" Assembly="GRCh37">
            <Expression>NC_000003.11:g.138665100_138665106del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.12" sequenceAccession="NC_000003" sequenceVersion="12" change="g.138946258_138946264del" Assembly="GRCh38">
            <Expression>NC_000003.12:g.138946258_138946264del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012454.1" sequenceAccession="NG_012454" sequenceVersion="1" change="g.5880_5886del">
            <Expression>NG_012454.1:g.5880_5886del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_029796.1" sequenceAccession="NG_029796" sequenceVersion="1" change="g.4025_4031del">
            <Expression>NG_029796.1:g.4025_4031del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_023067.4" sequenceAccession="NM_023067" sequenceVersion="4" change="c.462_468del" MANESelect="true">
            <Expression>NM_023067.4:c.462_468del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_075555.1" sequenceAccession="NP_075555" sequenceVersion="1" change="p.Pro156fs">
            <Expression>NP_075555.1:p.Pro156fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1295" sequenceAccession="LRG_1295">
            <Expression>LRG_1295:g.5880_5886del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1295t1" sequenceAccession="LRG_1295t1">
            <Expression>LRG_1295t1:c.462_468del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1295p1" sequenceAccession="LRG_1295p1" change="p.Pro156fs">
            <Expression>LRG_1295p1:p.Pro156fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA658796386" DB="ClinGen" />
        <XRef Type="rs" ID="1553752894" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_023067.4(FOXL2):c.462_468del (p.Pro156fs) AND Premature ovarian failure 3" Accession="RCV000625747" Version="2">
        <ClassifiedConditionList TraitSetID="1338">
          <ClassifiedCondition DB="MedGen" ID="C1837008">Premature ovarian failure 3</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2018-01-29" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2018-01-29" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2018-04-29" MostRecentSubmission="2018-04-29">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="1338" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5796" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Premature ovarian failure 3</ElementValue>
                <XRef ID="Premature+ovarian+failure+3/9150" DB="Genetic Alliance" />
                <XRef ID="MONDO:0012169" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">POF3</ElementValue>
                <XRef Type="MIM" ID="608996" DB="OMIM" />
              </Symbol>
              <XRef ID="C1837008" DB="MedGen" />
              <XRef ID="MONDO:0012169" DB="MONDO" />
              <XRef Type="MIM" ID="608996" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1453627" SubmissionDate="2018-03-26" DateLastUpdated="2018-04-29" DateCreated="2018-04-29">
        <ClinVarSubmissionID localKey="SUB3657114" submittedAssembly="hg19" title="SUB3657114" />
        <ClinVarAccession Accession="SCV000681413" DateUpdated="2018-04-29" DateCreated="2018-04-29" Type="SCV" Version="1" SubmitterName="Institute of Reproductive and Stem Cell Engineering, Central South University" OrgID="506234" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-01-29">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The novel mutation identified in the present study will enhance the present knowledge of the mutation spectrum of FOXL2. The in vitro experiments provide further insights into the molecular mechanism by which the new variant mediate disease pathogenesis and may contribute to elucidating the genotype-phenotype correlation between the novel FOXL2 mutation and POI.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Sporadic</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <NamePlatform>ABI9700</NamePlatform>
              <TypePlatform>PCR</TypePlatform>
              <Description>Genomic DNA was extracted from whole-blood leucocytes of patients using a QIAamp Blood DNA Mini kit (Qiagen, Hilden, Germany) according to the manufacturerâ€™s instructions. The entire coding region and intron-exon boundaries of FOXL2 were amplified from genomic DNA using poly- merase chain reaction (PCR) as previously described (Bell, Murday, Patton, &amp; Jeffery, 2001) and directly sequenced using the Applied Biosystems 3130 genetic analyser (ABI, USA).</Description>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>not applicable</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>not applicable</AffectedStatus>
            </Sample>
            <Method>
              <Description>Plasmid constructs, Cell culture and transient transfection, Immunofluorescence and confocal microscopy, Quantitative real-time PCR</Description>
              <MethodType>in vitro</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">The wild-type FOXL2 protein localizes exclusively in the nucleus in a diffused manner and cells transfected with the empty vector displayed significant cytoplasmic mislocalization. Cells transfected with the mutant construct (FOXL2-Pro156Argfs-EGFP) displayed the same pattern as cells transfected with the wild-type construct. The expression level of endogenous SIRT1 mRNA in cells transfected with the mutant construct (FOXL2-Pro156Argfs-EGFP) was higher than that in cells transfected with the wild-type FOXL2.</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_023067.3:c.462_468del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="608996" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">29378385</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB3657114</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1453627" TraitType="Disease" MappingType="XRef" MappingValue="608996" MappingRef="OMIM">
        <MedGen CUI="C1837008" Name="Premature ovarian failure 3" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

